BOSENTAN

Course overview

PULMONARY ARTERY HYPERTENSION HAS PROVEN TO CAUSE SIGNIFICANT MORTALITY AND MORBIDITY WORLDWIDE. THE FIRST-LINE TREATMENT OPTION FOR PULMONARY ARTERY HYPERTENSION HAS BEEN THE USE OF AN ENDOTHELIN 1 ANTAGONIST, SUCH AS BOSENTAN. BOSENTAN IS A MEDICATION USED IN THE MANAGEMENT AND TREATMENT OF PULMONARY ARTERY HYPERTENSION. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, TOXICITY, OFF-LABEL USE, DOSING, PHARMACODYNAMICS, AND MONITORING PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM FOR THE TREATMENT OF PATIENTS WITH PULMONARY ARTERY HYPERTENSION.